Researchers to examine cost-effectiveness of more new drugs | Democrats say Pacific trade deal would raise drug costs | Push to repeal ACA through reconciliation could begin soon
July 21, 2015
PCMA SmartBrief
News for the PBM Industry

Featured Story
Researchers to examine cost-effectiveness of more new drugs
A $5.2 million grant will allow the Institute of Clinical and Economic Review to conduct cost-effectiveness studies for up to 20 new medications. The institute last year found that novel hepatitis C drugs needed to be sold at about half their full price to have value. Modern Healthcare (tiered subscription model) (7/21), The Wall Street Journal (tiered subscription model) (7/21)
Share: LinkedInTwitterFacebookGoogle+Email
Legislative & Regulatory News
Democrats say Pacific trade deal would raise drug costs
Provisions being negotiated for the Trans-Pacific Partnership would reduce access to low-cost drugs internationally and in the U.S., according to Rep. Jan Schakowsky, D-Ill., and Rep. Rosa DeLauro, D-Conn. MedPage Today (free registration) (7/20)
Share: LinkedInTwitterFacebookGoogle+Email
Push to repeal ACA through reconciliation could begin soon
Republicans have a tentative deadline on Friday to begin the budget reconciliation process as a tool to repeal the Affordable Care Act. If a measure isn't ready, the process can be started later in the congressional year, according to Eric Zimmerman of McDermott+Consulting. Modern Healthcare (tiered subscription model) (7/17)
Share: LinkedInTwitterFacebookGoogle+Email
Study looks at what parents know about antibiotics
Researchers found that 44% and 38% of Medicaid parents correctly answered that antibiotics are not needed to treat a child's colds or flu, or green nasal discharge, respectively, compared with almost 80% and 53% of parents with private insurance. The findings in Pediatrics also revealed that the proportion of parents who rightly believed that antibiotics didn't remedy nasal discharge increased from 2000 to 2013. HealthDay News (7/20), Reuters (7/20)
Share: LinkedInTwitterFacebookGoogle+Email
Drug Industry Spotlight
Horizon raises offer for Depomed
Horizon Pharma has increased its all-stock bid for Depomed to $33 a share, up from $29.25 earlier this month. Depomed's directors said the previous offer was not in its shareholders' interest. The New York Times (single-article access for SmartBrief readers) (7/21)
Share: LinkedInTwitterFacebookGoogle+Email
162K cartons of medications pulled from market by Wockhardt
India-based Wockhardt has recalled 162,142 cartons of medications, including treatments for ulcers and hypertension, over concerns about compliance with manufacturing standards, according to the FDA. The Economic Times (India)/Press Trust of India (7/16)
Share: LinkedInTwitterFacebookGoogle+Email
Desire is the key to motivation, but it's determination and commitment to an unrelenting pursuit of your goal -- a commitment to excellence -- that will enable you to attain the success you seek."
-- Mario Andretti,
race car driver
Share: LinkedInTwitterFacebookGoogle+Email
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 216 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
(202) 207-3610
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tom Parks

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information